Clinical Trials Browser

Astrocytoma, Glioblastoma

Glioblastoma

Astrocytoma, Glioblastoma, Glioma

Glioblastoma

Astrocytoma, Glioblastoma, Lymphoma, Follicular

Glioblastoma, Gliosarcoma

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Astrocytoma, Glioblastoma, Gliosarcoma

Astrocytoma, Glioblastoma

Astrocytoma, Glioblastoma

Astrocytoma, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Lung Neoplasms

Glioblastoma

Glioblastoma

Glioblastoma

Glioblastoma, Glioma, Cholangiocarcinoma

Glioblastoma, Gliosarcoma

Glioblastoma

Glioblastoma, Gliosarcoma

Glioblastoma

Glioblastoma

Glioblastoma

Glioblastoma, Gliosarcoma

Glioblastoma

Glioblastoma

Astrocytoma, Glioblastoma, Lymphoma, Follicular

Glioblastoma

Glioblastoma

Glioblastoma, Glioma

Clinical Trials

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma

Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma